Mofenson, Lynne Meryl
Dr. Mofenson is MPID Branch Chief and responsible for extramural program planning, prioritization, development and scientific direction of domestic and international research studies and clinical trials in the prevention and treatment of pediatric, adolescent
and maternal HIV infection, tuberculosis, viral hepatitis, and other priority infectious diseases in these populations.
15117 TIMBERLAKE DRIVE
Silver Spring ,MD 20905
Lynne M. Mofenson, M.D., is an infectious disease specialist and board-certified pediatrician who joined the PAMA Branch in 1989. She received her M.D. from Albert Einstein College of Medicine with honors (Alpha Omega Alpha). Dr. Mofenson is PAMA Branch Chief, responsible for overall program planning and the development and scientific direction of research studies and clinical trials in domestic and international pediatric, adolescent, and maternal HIV infection, disease, and AIDS. She is also project officer for the NICHD-funded multi-site Domestic and International Pediatric/Perinatal HIV Clinical Studies Network, which conducts clinical trials in treatment and management of HIV infection in infants, children, adolescents, and women both domestically and internationally, often in collaboration with other Networks, such as the Pediatric AIDS Clinical Trials Group funded by the NIAID, the Adolescent Trials Network and the Pediatric European Network for Treatment of AIDS. She serves as Executive Secretary for the U.S. Public Health Service guidelines for treatment of HIV-infected children, treatment of HIV-infected pregnant women and prevention of mother to child HIV transmission, and provides consultation to the World Health Organization on treatment guidelines in resource-limited countries.
Panel on Treatment of HIV-Infected Pregnant Women and Prevention of Perinatal Transmission. Recommendations for Use of Antiretroviral Drugs in Pregnant HIV-1-Infected Women for Maternal Health and Interventions to Reduce Perinatal HIV Transmission in the United States. Available at http://aidsinfo.nih.gov/contentfiles/lvguidelines/PerinatalGL.pdf (PDF - 1.51. MB).
Panel on Antiretroviral Therapy and Medical Management of HIV-Infected Children. Guidelines for the Use of Antiretroviral Agents in Pediatric HIV Infection. Available at http://aidsinfo.nih.gov/contentfiles/lvguidelines/pediatricguidelines.pdf (PDF - 2.69 MB).
Centers for Disease Control and Prevention. Guidelines for the Prevention and Treatment of Opportunistic Infections Among HIV-Exposed and HIV-Infected Children. MMWR 2009;58 (No. RR-11) September 4, 2009
|Adherence to antiretroviral therapy during and after pregnancy in low-income, middle-income, and high-income countries: a systematic review and meta-analysis.||Nachega JB,Uthman OA,Anderson J,Peltzer K,Wampold S,Cotton MF,Mills EJ,Ho YS,Stringer JS,McIntyre JA,Mofenson LM||AIDS||2012 Oct 23|
|Unresolved antiretroviral treatment management issues in HIV-infected children.||Heidari S,Mofenson LM,Hobbs CV,Cotton MF,Marlink R,Katabira E||J Acquir Immune Defic Syndr||2012 Feb 1|
|Nevirapine versus ritonavir-boosted lopinavir for HIV-infected children.||Violari A,Lindsey JC,Hughes MD,Mujuru HA,Barlow-Mosha L,Kamthunzi P,Chi BH,Cotton MF,Moultrie H,Khadse S,Schimana W,Bobat R,Purdue L,Eshleman SH,Abrams EJ,Millar L,Petzold E,Mofenson LM,Jean-Philippe P,Palumbo P||N Engl J Med||2012 Jun 21|
|Three postpartum antiretroviral regimens to prevent intrapartum HIV infection.||Nielsen-Saines K,Watts DH,Veloso VG,Bryson YJ,Joao EC,Pilotto JH,Gray G,Theron G,Santos B,Fonseca R,Kreitchmann R,Pinto J,Mussi-Pinhata MM,Ceriotto M,Machado D,Bethel J,Morgado MG,Dickover R,Camarca M,Mirochnick M,Siberry G,Grinsztejn B,Moreira RI,Bastos FI,Xu J,Moye J,Mofenson LM,NICHD HPTN 040/PACTG 1043 Protocol Team||N Engl J Med||2012 Jun 21|
|Efficacy and safety of an extended nevirapine regimen in infant children of breastfeeding mothers with HIV-1 infection for prevention of postnatal HIV-1 transmission (HPTN 046): a randomised, double-blind, placebo-controlled trial.||Coovadia HM,Brown ER,Fowler MG,Chipato T,Moodley D,Manji K,Musoke P,Stranix-Chibanda L,Chetty V,Fawzi W,Nakabiito C,Msweli L,Kisenge R,Guay L,Mwatha A,Lynn DJ,Eshleman SH,Richardson P,George K,Andrew P,Mofenson LM,Zwerski S,Maldonado Y,HPTN 046 protocol team||Lancet||2012 Jan 21|
|Safety of tenofovir use during pregnancy: early growth outcomes in HIV-exposed uninfected infants.||Siberry GK,Williams PL,Mendez H,Seage GR 3rd,Jacobson DL,Hazra R,Rich KC,Griner R,Tassiopoulos K,Kacanek D,Mofenson LM,Miller T,DiMeglio LA,Watts DH,Pediatric HIV/AIDS Cohort Study (PHACS)||AIDS||2012 Jun 1|
|Safety of efavirenz in the first trimester of pregnancy: an updated systematic review and meta-analysis.||Ford N,Calmy A,Mofenson L||AIDS||2011 Nov 28|
|Prevention of mother-to-child HIV-1 transmission--why we still need a preventive HIV immunization strategy.||Mofenson LM||J Acquir Immune Defic Syndr||2011 Dec 1|
|Antiretroviral drugs for preventing mother-to-child transmission of HIV: a review of potential effects on HIV-exposed but uninfected children.||Heidari S,Mofenson L,Cotton MF,Marlink R,Cahn P,Katabira E||J Acquir Immune Defic Syndr||2011 Aug 1|
|Prevention in neglected subpopulations: prevention of mother-to-child transmission of HIV infection.||Mofenson LM||Clin Infect Dis||2010 May 15|
|Protecting the next generation--eliminating perinatal HIV-1 infection.||Mofenson LM||N Engl J Med||2010 Jun 17|
|Antiretroviral drugs to prevent breastfeeding HIV transmission.||Mofenson LM||Antivir Ther||2010|
|Antiretroviral treatment for children with peripartum nevirapine exposure.||Palumbo P,Lindsey JC,Hughes MD,Cotton MF,Bobat R,Meyers T,Bwakura-Dangarembizi M,Chi BH,Musoke P,Kamthunzi P,Schimana W,Purdue L,Eshleman SH,Abrams EJ,Millar L,Petzold E,Mofenson LM,Jean-Philippe P,Violari A||N Engl J Med||2010 Oct 14|
|First-line antiretroviral therapy with a protease inhibitor versus non-nucleoside reverse transcriptase inhibitor and switch at higher versus low viral load in HIV-infected children: an open-label, randomised phase 2/3 trial.||PENPACT-1 (PENTA 9/PACTG 390) Study Team,Babiker A,Castro nee Green H,Compagnucci A,Fiscus S,Giaquinto C,Gibb DM,Harper L,Harrison L,Hughes M,McKinney R,Melvin A,Mofenson L,Saidi Y,Smith ME,Tudor-Williams G,Walker AS||Lancet Infect Dis||2011 Apr|
|The challenges of success: adolescents with perinatal HIV infection.||Mofenson LM,Cotton MF||J Int AIDS Soc||2013 Jun 18|
|Cognitive Function and Neurodevelopmental Outcomes in HIV-Infected Children Older than 1 Year of Age Randomized to Early Versus Deferred Antiretroviral Therapy: The PREDICT Neurodevelopmental Study.||Puthanakit T,Ananworanich J,Vonthanak S,Kosalaraksa P,Hansudewechakul R,van der Lugt J,Kerr SJ,Kanjanavanit S,Ngampiyaskul C,Wongsawat J,Luesomboon W,Vibol U,Pruksakaew K,Suwarnlerk T,Apornpong T,Ratanadilok K,Paul R,Mofenson LM,Fox L,Valcour V,Brouwers P,Ruxrungtham K||Pediatr Infect Dis J||2013 Jan 2|
|Tenofovir Treatment Duration Predicts Proteinuria in a Multi-Ethnic United States Cohort of Children and Adolescents with Perinatal HIV-1 Infection.||Purswani M,Patel K,Kopp JB,Seage GR 3rd,Chernoff MC,Hazra R,Siberry GK,Mofenson LM,Scott GB,Van Dyke RB,for the Pediatric HIVAIDS Cohort Study||Pediatr Infect Dis J||2012 Dec 17|
|Impact of maternal and infant antiretroviral drug regimens on drug resistance in HIV-infected breastfeeding infants.||Fogel JM,Mwatha A,Richardson P,Brown ER,Chipato T,Alexandre M,Moodley D,Elbireer A,Mirochnick M,George K,Mofenson LM,Zwerski S,Coovadia HM,Eshleman SH||Pediatr Infect Dis J||2013 Apr|
|Combination antiretroviral use and preterm birth.||Watts DH,Williams PL,Kacanek D,Griner R,Rich K,Hazra R,Mofenson LM,Mendez HA,Pediatric HIV/AIDS Cohort Study||J Infect Dis||2013 Feb 15|
|Outcomes of antiretroviral therapy in children in Asia and Africa: a comparative analysis of the IeDEA pediatric multiregional collaboration.||Leroy V,Malateste K,Rabie H,Lumbiganon P,Ayaya S,Dicko F,Davies MA,Kariminia A,Wools-Kaloustian K,Aka E,Phiri S,Aurpibul L,Yiannoutsos C,Signaté-Sy H,Mofenson L,Dabis F,International IeDEA Pediatric Working Group1||J Acquir Immune Defic Syndr||2013 Feb 1|
|Estimates of peripartum and postnatal mother-to-child transmission probabilities of HIV for use in Spectrum and other population-based models.||Rollins N,Mahy M,Becquet R,Kuhn L,Creek T,Mofenson L||Sex Transm Infect||2012 Dec|
|Antiretrovirals in pregnancy: a note of caution.||Watts DH,Mofenson LM||J Infect Dis||2012 Dec 1|
|Early versus deferred antiretroviral therapy for children older than 1 year infected with HIV (PREDICT): a multicentre, randomised, open-label trial.||Puthanakit T,Saphonn V,Ananworanich J,Kosalaraksa P,Hansudewechakul R,Vibol U,Kerr SJ,Kanjanavanit S,Ngampiyaskul C,Wongsawat J,Luesomboon W,Ngo-Giang-Huong N,Chettra K,Cheunyam T,Suwarnlerk T,Ubolyam S,Shearer WT,Paul R,Mofenson LM,Fox L,Law MG,Cooper DA,Phanuphak P,Vun MC,Ruxrungtham K,PREDICT Study Group||Lancet Infect Dis||2012 Dec|
|Progress, challenges, and new opportunities for the prevention of mother-to-child transmission of HIV under the US President's Emergency Plan for AIDS Relief.||Chi BH,Adler MR,Bolu O,Mbori-Ngacha D,Ekouevi DK,Gieselman A,Chipato T,Luo C,Phelps BR,McClure C,Mofenson LM,Stringer JS||J Acquir Immune Defic Syndr||2012 Aug 15|